Aa
Co-infection Study - ATTN NashPred
J Hepatol. 2008 Apr 29. [Epub ahead of print]
The HEP-NET B/C co-infection trial: A prospective multicenter study to
investigate the efficacy of pegylated interferon-alpha2b and ribavirin in
patients with HBV/HCV co-infection.
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U,
Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K,
Manns MP, Trautwein C; for the Hep-Net B/C Co-infection Study Group.
Department of Gastroenterology, Hepatology and Endocrinology, Medizinische
Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany.
BACKGROUND/AIMS: The efficacy of pegylated interferon alpha and ribavirin in
HBV/HCV co-infected patients is unknown. METHODS: Nineteen patients with
chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9
HCV-genotype 2 or 3) were included in this prospective multicenter pilot
study. Baseline HBV-DNA was negative in 13 individuals. All patients received
weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks. RESULTS: In the
intent-to-treat analysis, a biochemical and an HCV-RNA response were observed
in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment
as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in
patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3
infection). Two of the five initially HBV-DNA positive patients with follow-up
available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA
became detectable after the clearance of HCV in four initially HBV-DNA
negative patients. CONCLUSIONS: Combination therapy with PEG-IFN-a2b and
ribavirin is highly effective in inducing a virological response concerning
HCV in patients with HBV/HCV co-infection. However, HBV replication may
increase after the clearance of HCV and thus close monitoring for both the
viruses is recommended even in patients with initially undetectable HBV-DNA.
The HEP-NET B/C co-infection trial: A prospective multicenter study to
investigate the efficacy of pegylated interferon-alpha2b and ribavirin in
patients with HBV/HCV co-infection.
Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U,
Gruengreiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K,
Manns MP, Trautwein C; for the Hep-Net B/C Co-infection Study Group.
Department of Gastroenterology, Hepatology and Endocrinology, Medizinische
Hochschule Hannover, Carl-Neuberg-Str. 1, 30623 Hannover, Germany.
BACKGROUND/AIMS: The efficacy of pegylated interferon alpha and ribavirin in
HBV/HCV co-infected patients is unknown. METHODS: Nineteen patients with
chronic HBV/HCV co-infection (HBsAg and HCV-RNA positive; 10 HCV-genotype 1; 9
HCV-genotype 2 or 3) were included in this prospective multicenter pilot
study. Baseline HBV-DNA was negative in 13 individuals. All patients received
weight-adjusted PEG-IFN-alpha2b and ribavirin for 48 weeks. RESULTS: In the
intent-to-treat analysis, a biochemical and an HCV-RNA response were observed
in 12 and 14 patients, respectively (63% and 74%). At the end of the treatment
as well as at the end of the follow-up the HCV-RNA response was 93% (14/15) in
patients adherent to therapy (86% in genotype 1 and 100% in genotypes 2 and 3
infection). Two of the five initially HBV-DNA positive patients with follow-up
available were HBV-DNA negative at follow-up week 24. In contrast, HBV-DNA
became detectable after the clearance of HCV in four initially HBV-DNA
negative patients. CONCLUSIONS: Combination therapy with PEG-IFN-a2b and
ribavirin is highly effective in inducing a virological response concerning
HCV in patients with HBV/HCV co-infection. However, HBV replication may
increase after the clearance of HCV and thus close monitoring for both the
viruses is recommended even in patients with initially undetectable HBV-DNA.
Alright, alright, I admit it....Zelly and cajim became Research Locating Wizards.
So....we were correct on our assumption :)
So....we were correct on our assumption :)
Thank you sooooo much zelly. This is the most recent data I have seen.
This also helps to show the need to start on HBV anit-virals at end of PEG-IFN tx.
If I can just get rid of the HCV, I have no problem LIVING with HBV. I can see by this board that I'm in good company.
Good stuff.
This also helps to show the need to start on HBV anit-virals at end of PEG-IFN tx.
If I can just get rid of the HCV, I have no problem LIVING with HBV. I can see by this board that I'm in good company.
Good stuff.
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
